CA3065318A1 - Methods for treatment of fibrotic diseases - Google Patents
Methods for treatment of fibrotic diseasesInfo
- Publication number
- CA3065318A1 CA3065318A1 CA3065318A CA3065318A CA3065318A1 CA 3065318 A1 CA3065318 A1 CA 3065318A1 CA 3065318 A CA3065318 A CA 3065318A CA 3065318 A CA3065318 A CA 3065318A CA 3065318 A1 CA3065318 A1 CA 3065318A1
- Authority
- CA
- Canada
- Prior art keywords
- group
- pulmonary fibrosis
- alkyl
- compound
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762514541P | 2017-06-02 | 2017-06-02 | |
| US62/514,541 | 2017-06-02 | ||
| PCT/US2018/035646 WO2018223023A1 (en) | 2017-06-02 | 2018-06-01 | Methods for treatment of fibrotic diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3065318A1 true CA3065318A1 (en) | 2018-12-06 |
Family
ID=64456126
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3065318A Pending CA3065318A1 (en) | 2017-06-02 | 2018-06-01 | Methods for treatment of fibrotic diseases |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US11298346B2 (enExample) |
| EP (2) | EP4656191A1 (enExample) |
| JP (1) | JP7159302B2 (enExample) |
| CA (1) | CA3065318A1 (enExample) |
| WO (1) | WO2018223023A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4656191A1 (en) * | 2017-06-02 | 2025-12-03 | Iterion Therapeutics, Inc. | Methods for treatment of fibrotic diseases |
| WO2019099836A1 (en) * | 2017-11-16 | 2019-05-23 | Northwestern University | Inhaled formulation of a molecular inhibitor of wnt/beta-catenin signaling for treating interstitial lung diseases |
| CA3101994A1 (en) * | 2018-06-01 | 2019-12-05 | Iterion Therapeutics, Inc. | Formulations of tegavivint and related compounds |
| EP4081209A4 (en) * | 2019-12-24 | 2024-04-24 | The Regents of the University of California | Compositions and methods for treating cancer and improving epithelial homeostasis |
| CA3176457A1 (en) * | 2020-04-08 | 2021-10-14 | The Trustees Of Indiana University | Therapeutic strategies to manage facial contractures post injury |
| US11136307B1 (en) * | 2020-09-29 | 2021-10-05 | Iterion Therapeutics, Inc. | Crystalline form of tegavivint, method of preparation, and use thereof |
| US11964054B2 (en) | 2020-11-24 | 2024-04-23 | Iterion Therapeutics, Inc. | Formulations of tegavivint |
| US11571388B2 (en) | 2020-11-24 | 2023-02-07 | Iterion Therapeutics, Inc. | Lyophilized formulations of tegavivint |
| CN119215047A (zh) * | 2024-10-11 | 2024-12-31 | 浙江大学 | 一种芳香磺酰胺类化合物在制备防治肝损伤药物中的应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2871493C (en) * | 2007-05-10 | 2017-03-28 | Dogwood Pharmaceuticals, Inc. | Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof |
| EA030302B1 (ru) | 2008-11-21 | 2018-07-31 | Форест Лэборетериз Холдингз Лимитед | Антрахинондиоксимы и их применение |
| ES2594900T3 (es) * | 2009-12-15 | 2016-12-23 | The Hospital For Sick Children | Método para tratar cicatrices y trastornos mediados por beta-catenina |
| AU2012332111B2 (en) * | 2011-11-06 | 2016-11-17 | Beta Cat Pharmaceuticals, Llc | Methods for treatment of diseases and disorders related to transducin beta-like protein 1 (TBL 1) activity, including myeloproliferative neoplasia and chronic myeloid leukemia |
| US20130123281A1 (en) * | 2011-11-11 | 2013-05-16 | Beta Cat Pharmaceuticals, Llc | Compositions and Methods for Inhibition of TBL-1 Binding to Disease-Associated Molecules |
| CA2905841A1 (en) * | 2013-03-14 | 2014-10-02 | Curegenix, Inc. | Quinazoline and naphthyridine derivatives useful in the treatment of fibrotic disorders |
| US9725473B2 (en) | 2015-07-28 | 2017-08-08 | Beta Cat Pharmaceuticals, Inc. | Anthracene-9, 10-dione dioxime compound prodrugs and their uses |
| KR102651136B1 (ko) * | 2016-04-12 | 2024-03-25 | 삼성디스플레이 주식회사 | 유기 발광 표시 장치 및 그 제조 방법 |
| EP4656191A1 (en) * | 2017-06-02 | 2025-12-03 | Iterion Therapeutics, Inc. | Methods for treatment of fibrotic diseases |
| CA3101994A1 (en) * | 2018-06-01 | 2019-12-05 | Iterion Therapeutics, Inc. | Formulations of tegavivint and related compounds |
| US11571388B2 (en) * | 2020-11-24 | 2023-02-07 | Iterion Therapeutics, Inc. | Lyophilized formulations of tegavivint |
-
2018
- 2018-06-01 EP EP25199000.8A patent/EP4656191A1/en active Pending
- 2018-06-01 CA CA3065318A patent/CA3065318A1/en active Pending
- 2018-06-01 US US15/995,917 patent/US11298346B2/en active Active
- 2018-06-01 JP JP2020516787A patent/JP7159302B2/ja active Active
- 2018-06-01 EP EP18809912.1A patent/EP3630101B1/en active Active
- 2018-06-01 WO PCT/US2018/035646 patent/WO2018223023A1/en not_active Ceased
-
2022
- 2022-03-29 US US17/707,486 patent/US20230012615A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3630101B1 (en) | 2025-10-08 |
| JP7159302B2 (ja) | 2022-10-24 |
| WO2018223023A1 (en) | 2018-12-06 |
| US20230012615A1 (en) | 2023-01-19 |
| JP2020522567A (ja) | 2020-07-30 |
| US11298346B2 (en) | 2022-04-12 |
| EP4656191A1 (en) | 2025-12-03 |
| EP3630101A4 (en) | 2021-01-20 |
| US20180344713A1 (en) | 2018-12-06 |
| EP3630101A1 (en) | 2020-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230012615A1 (en) | Methods for treatment of fibrotic diseases | |
| KR101855358B1 (ko) | 골암통증에서의 시그마 리간드의 용도 | |
| EP1256576B1 (en) | Fused imidazolium derivatives | |
| JP2025010154A (ja) | 線維症及び炎症の処置のための組成物 | |
| US20080221078A1 (en) | Use of a CB1 Antagonist for Treating Side Effects and Negative Symptoms of Schizophrenia | |
| JP2009541223A5 (enExample) | ||
| KR20100126434A (ko) | 피리다진 유도체 및 피부 장애의 치료에서의 치료제로서의 그의 용도 | |
| KR20050042154A (ko) | 통증의 치료에 사용하기 위한 알파-2-델타 리간드와 ｐｄｅｖ 억제제의 상승작용 조합물 | |
| CN114026072A (zh) | 治疗特发性肺纤维化的方法 | |
| JP2014196328A (ja) | ニコチン性アセチルコリンα７受容体アゴニストの組合せ剤 | |
| KR20160067118A (ko) | (ｓ)-3-(4-((4-(모르폴리노메틸)벤질)옥시)-1-옥소이소인돌린-2-일)피페리딘-2,6-디온의 제제 | |
| WO2007095383A2 (en) | Prodrugs | |
| EP3484862A1 (en) | Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia | |
| US20240390399A1 (en) | Materials and methods for suppressing and/or treating bone related diseases and symptoms | |
| EP1852112A1 (en) | Anti-tumor agent | |
| MX2009002311A (es) | Composiciones farmaceuticas para tratamiento de infecciones fungales. | |
| EP3573957B1 (en) | Compositions and methods for blocking sodium channels | |
| JP7665529B2 (ja) | ジアミノピリミジン化合物を使用することによって咳を治療する方法 | |
| EP3833354B1 (en) | Tissue transglutaminase modulators for medicinal use | |
| RS53896B1 (sr) | Pantenil dokosaheksaenoat i njegova upotreba za lečenje i prevenciju kardiovaskularnih oboljenja | |
| WO2005011684A1 (de) | Arzneimittel enthaltend derivate von aryl(oder heteroaryl)azolylcarbinolen | |
| EP2676954A1 (en) | Heterocyclyl-substituted-phenyl derivatives as vasodilators | |
| EP3424506B1 (en) | Pharmaceutical composition for treating functional psychiatric disorders | |
| TW201806601A (zh) | σ受體配體在皰疹後遺疼痛中的用途 | |
| JP2003267871A (ja) | 放射線障害予防剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20230525 |
|
| EEER | Examination request |
Effective date: 20230525 |